Rockefeller Capital Management’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$318K Sell
12,315
-417
-3% -$11.8K ﹤0.01% 2392
2026
Q2
$393K Sell
12,732
-197
-2% -$4.87K ﹤0.01% 2218
2026
Q1
$279K Buy
12,929
+705
+6% +$15.2K ﹤0.01% 2298
2025
Q4
$291K Buy
12,224
+8,368
+217% +$171K ﹤0.01% 2172
2025
Q3
$52.4K Buy
+3,856
New +$40.1K ﹤0.01% 2891
2023
Q1
– Sell
-8,596
Closed -$177K – 3473
2022
Q4
$177K Hold
8,596
– – ﹤0.01% 1720
2022
Q3
$224K Sell
8,596
-129
-1% -$3.41K ﹤0.01% 1603
2022
Q2
$220K Buy
+8,725
New +$214K ﹤0.01% 1597

Other funds holding RCUS

Rockefeller Capital Management's RCUS Position: Q3 2026 in Review

Rockefeller Capital Management reduced its Arcus Biosciences (RCUS) stake by 3.3% in Q3 2026, selling an estimated $11.8K and leaving 12,315 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #2392.

Rockefeller Capital Management first reported a position in RCUS in Q2 2022 and has held it in 8 quarters since. The position peaked at $393K in Q2 2026. 177 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • Rockefeller Capital Management held 12,315 shares of Arcus Biosciences worth $318K as of Q3 2026.
  • Rockefeller Capital Management sold 417 Arcus Biosciences shares in Q3 2026, an estimated $11.8K.
  • Arcus Biosciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #2392 holding.
  • Rockefeller Capital Management first reported a position in Arcus Biosciences in Q2 2022 and has held it in 8 quarters since.
  • Rockefeller Capital Management's Arcus Biosciences position peaked at $393K in Q2 2026.
  • 177 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.